Phenominer Database Results (67 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Formula Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
LOU/M post-treatment survival time from drug-treated IgM immunocytoma rat IgM immunocytoma cells (1 x 10E4 cells) then cisplatin (4 mg/kg) (for 42 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. life span trait both 154 days-193 days 7 31.0 d 1.51 4.0 necropsy 0.0 0 post-treatment survival time from drug-treated IgM immunocytoma (CMO:0003867) 109476 3146
LOU/M post-treatment survival time from drug-treated IgM immunocytoma rat IgM immunocytoma cells (1 x 10E4 cells) then cisplatin (2 mg/kg) (for 49 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. life span trait both 154 days-193 days 7 35.0 d 2.65 7.0 necropsy 0.0 0 post-treatment survival time from drug-treated IgM immunocytoma (CMO:0003867) 109477 3146
LOU/M post-insult time to onset of experimental autoimmune encephalomyelitis Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) and cyclophosphamide (8 mg) then cyclophosphamide (5 mg) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 4 11.0 d 0.0 0.0 in vivo visual assessment 2592000.0 0 110797 3186
LOU/M time from start of drug therapy to immunocytoma regrowth rat IgM immunocytoma cells (1 x 10E4 cells) then cisplatin (0.5 mg/kg) (for 21 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 19.2 d 3.2 in vivo caliper method 0.0 0 Experiment 2 109493 3146
LOU/M time from therapy-induced maximal immunocytoma size decrease to regrowth of tumor to a diameter of 10 mm rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (0.5 mg/kg) (for 7 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 6.8 d 3.6 in vivo caliper method 0.0 0 Experiment 2 109499 3146
LOU/M time from therapy-induced maximal immunocytoma size decrease to regrowth of tumor to a diameter of 10 mm rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (1 mg/kg) (for 7 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 7.2 d 4.1 in vivo caliper method 0.0 0 Experiment 2 109500 3146
LOU/M percentage of study population developing experimental autoimmune encephalomyelitis during a period of time Freund's complete adjuvant (0.05-0.1 ml) and Hu-S102-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 3 100.0 % 0.0 0.0 in vivo visual assessment 2592000.0 0 110794 3186
LOU/M percentage of study population developing experimental autoimmune encephalomyelitis during a period of time Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 4 100.0 % 0.0 0.0 in vivo visual assessment 2592000.0 0 110795 3186
LOU/M percent protection by treatment for Schistosoma mansoni rat anti-Ab2 T cell line (10-15 x 10E6 cells) (for 90 days) then Schistosoma mansoni cercariae (1500 null) (for 21 days) Velge-Roussel F, etal., J Immunol. 1991 Dec 1;147(11):3967-72. response to parasitic infection trait male 201 days 3 (a-b/a)x100 57.0 % computational method 0.0 90 days S. mansoni infection 90 day post pretreatment 109258 3139
LOU/M body weight control condition van Hoesel QG, etal., J Natl Cancer Inst. 1986 Feb;76(2):299-307. body mass male 84 days 43 259.0 g 3.2 21.0 body weighing method 0.0 0 109289 3144
LOU/M serum creatinine level control condition van Hoesel QG, etal., J Natl Cancer Inst. 1986 Feb;76(2):299-307. blood creatinine amount female 84 days 43 0.43 mg/dl 0.01 0.03 serum creatinine analysis 0.0 0 109291 3144
LOU/M serum creatinine level doxorubicin (1 mg/kg) (for 49 days) van Hoesel QG, etal., J Natl Cancer Inst. 1986 Feb;76(2):299-307. blood creatinine amount female 133 days 43 0.61 mg/dl 0.0 0.03 serum creatinine analysis 0.0 XCO:0000539 49 days intravenous 109293 3144
LOU/M post-treatment survival time from drug-treated IgM immunocytoma rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (8 mg/kg) (for 49 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. life span trait both 154 days-193 days 7 32.0 d 0.38 1.0 necropsy 0.0 0 post-treatment survival time from drug-treated IgM immunocytoma (CMO:0003867) 109471 3146
LOU/M maximum tumor size decrease to pretreatment tumor size ratio rat IgM immunocytoma cells (1 x 10E4 cells) then cisplatin (1 mg/kg) (for 21 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 89.8 % 14.0 in vivo caliper method 0.0 0 Experiment 2 109489 3146
LOU/M maximum tumor size decrease to pretreatment tumor size ratio rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (0.5 mg/kg) (for 21 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 63.6 % 31.2 in vivo caliper method 0.0 0 Experiment 2 109491 3146
LOU/M post-insult time to onset of experimental autoimmune encephalomyelitis Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 4 11.0 d 0.0 0.0 in vivo visual assessment 2592000.0 0 110799 3186
LOU/M experimental autoimmune encephalomyelitis duration rat anti-Hu-S102-129 T cell line (9 x 10E6 cells) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 3 8.0 d 0.0 0.0 in vivo visual assessment 0.0 0 110789 3186
LOU/M time from start of drug therapy to immunocytoma regrowth rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (1 mg/kg) (for 28 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 28.0 d 8.7 in vivo caliper method 0.0 0 Experiment 1 109485 3146
LOU/M percentage of study population developing experimental autoimmune encephalomyelitis during a period of time Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 5 100.0 % 0.0 0.0 in vivo visual assessment 2592000.0 0 110792 3186
LOU/M post-insult time to onset of experimental autoimmune encephalomyelitis rat anti-Hu-MBP T cell line (9 x 10E6 cells) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 9 6.0 d 1.0 3.0 in vivo visual assessment 0.0 0 110783 3186
LOU/M percent protection by treatment for Schistosoma mansoni rat anti-Ab2 antiserum (1 ml) (for 1 days) then Schistosoma mansoni cercariae (1500 null) (for 21 days) Velge-Roussel F, etal., J Immunol. 1991 Dec 1;147(11):3967-72. response to parasitic infection trait male 112 days 5 (a-b/a)x100 37.0 % computational method 0.0 1 days S. mansoni infection 1 day post pretreatment 109264 3139
LOU/M body weight control condition van Hoesel QG, etal., J Natl Cancer Inst. 1986 Feb;76(2):299-307. body mass female 84 days 43 162.0 g 1.83 12.0 body weighing method 0.0 0 109290 3144
LOU/M serum creatinine level doxorubicin (1 mg/kg) (for 35 days) van Hoesel QG, etal., J Natl Cancer Inst. 1986 Feb;76(2):299-307. blood creatinine amount female 119 days 43 0.57 mg/dl 0.0 0.02 serum creatinine analysis 0.0 XCO:0000539 35 days 109292 3144
LOU/M maximum tumor size decrease to pretreatment tumor size ratio rat IgM immunocytoma cells (1 x 10E4 cells) then cisplatin (1 mg/kg) (for 21 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 100.0 % 0.0 in vivo caliper method 0.0 0 Experiment 1 109481 3146
LOU/M maximum tumor size decrease to pretreatment tumor size ratio rat IgM immunocytoma cells (1 x 10E4 cells) then cisplatin (0.25 mg/kg) (for 21 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 29.3 % 23.3 in vivo caliper method 0.0 0 Experiment 2 109487 3146
LOU/M maximum tumor size decrease to pretreatment tumor size ratio rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (0.25 mg/kg) (for 21 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 -2.5 % 15.9 in vivo caliper method 0.0 0 Experiment 2 109490 3146
LOU/M maximum tumor size decrease to pretreatment tumor size ratio rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (1 mg/kg) (for 21 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 95.8 % 9.4 in vivo caliper method 0.0 0 Experiment 2 109492 3146
LOU/M post-insult time to onset of experimental autoimmune encephalomyelitis rat anti-Hu-S102-129 T cell line (9 x 10E6 cells) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 3 5.0 d 0.0 0.0 in vivo visual assessment 0.0 0 110782 3186
LOU/M experimental autoimmune encephalomyelitis duration Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 5 8.0 d 0.0 0.0 in vivo visual assessment 2592000.0 0 110800 3186
LOU/M time from therapy-induced maximal immunocytoma size decrease to regrowth of tumor to a diameter of 10 mm rat IgM immunocytoma cells (1 x 10E4 cells) then cisplatin (1 mg/kg) (for 7 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 8.6 d 3.4 in vivo caliper method 0.0 0 Experiment 2 109498 3146
LOU/M percent protection by treatment for Schistosoma mansoni rat anti-Ab2 T cells (10-15 x 10E6 cells) (for 1 days) then Schistosoma mansoni cercariae (1500 null) (for 21 days) Velge-Roussel F, etal., J Immunol. 1991 Dec 1;147(11):3967-72. response to parasitic infection trait male 112 days 3 (a-b/a)x100 27.0 % computational method 0.0 1 days S. mansoni infection 1 day post pretreatment 109255 3139
LOU/M percent protection by treatment for Schistosoma mansoni rat anti-26 kDa antiserum (1 ml) (for 1 days) then Schistosoma mansoni cercariae (1500 null) (for 21 days) Velge-Roussel F, etal., J Immunol. 1991 Dec 1;147(11):3967-72. response to parasitic infection trait male 112 days 5 (a-b/a)x100 21.0 % computational method 0.0 1 days S. mansoni infection 1 day post pretreatment 109265 3139
LOU/M liver adult Schistosoma mansoni worm count rat anti-Ab2 T cell line (10-15 x 10E6 cells) (for 1 days) then Schistosoma mansoni cercariae (1500 null) (for 21 days) Velge-Roussel F, etal., J Immunol. 1991 Dec 1;147(11):3967-72. parasite quantity male 112 days 3 count 170.0 null total organ perfusion and parasite count liver 0.0 1 days total organ perfusion and parasite count (MMO:0000750) 109268 3139
LOU/M percentage of study population developing experimental autoimmune encephalomyelitis during a period of time Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) and cyclophosphamide (5 mg) then cyclophosphamide (8 mg) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 4 100.0 % 0.0 0.0 in vivo visual assessment 2592000.0 0 110793 3186
LOU/M percentage of study population developing intestine tumors during a period of time control condition Bazin H, etal., Cancer Lett. 1980 Feb;8(4):353-7. doi: 10.1016/0304-3835(80)90152-4. intestine integrity trait both 240 days-720 days 163 0.6 % manual palpation method 0.0 0 108047 3114
LOU/M percent protection by treatment for Schistosoma mansoni rat serum from subject bearing a B48-14 IgE-producing hybridoma (0.5 ml) then Schistosoma mansoni cercariae (800 null) Verwaerde C, etal., J Immunol. 1987 Jun 15;138(12):4441-6. response to parasitic infection trait male 111 days 5 (a-b/a)x100 43.0 % total organ perfusion and parasite count liver 0.0 Schistosoma mansoni cercariae 21 days compared to saline, experiment 2 110809 3190
LOU/M percent protection by treatment for Schistosoma mansoni rat serum from subject bearing a B48-14 IgE-producing hybridoma (0.5 ml) then Schistosoma mansoni cercariae (800 null) Verwaerde C, etal., J Immunol. 1987 Jun 15;138(12):4441-6. response to parasitic infection trait male 111 days 5 (a-b/a)x100 49.0 % total organ perfusion and parasite count liver 0.0 Schistosoma mansoni cercariae 21 days compared to saline, experiment 3 110810 3190
LOU/M percentage of study population developing experimental autoimmune encephalomyelitis during a period of time rat anti-Hu-MBP T cell line (9 x 10E6 cells) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 9 100.0 % in vivo visual assessment 0.0 0 110780 3186
LOU/M post-insult time to onset of experimental autoimmune encephalomyelitis Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 5 11.0 d 0.0 0.0 in vivo visual assessment 2592000.0 0 110796 3186
LOU/M post-insult time to onset of experimental autoimmune encephalomyelitis Freund's complete adjuvant (0.05-0.1 ml) and Hu-S102-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 3 11.0 d 0.0 0.0 in vivo visual assessment 2592000.0 0 110798 3186
LOU/M percentage of study population developing experimental autoimmune encephalomyelitis during a period of time Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 4 0.0 % 0.0 0.0 in vivo visual assessment 2592000.0 0 110790 3186
LOU/M time from start of drug therapy to immunocytoma regrowth rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (0.5 mg/kg) (for 21 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 19.4 d 2.2 in vivo caliper method 0.0 0 Experiment 2 109495 3146
LOU/M time from start of drug therapy to immunocytoma regrowth rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (1 mg/kg) (for 21 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 20.2 d 5.2 in vivo caliper method 0.0 0 Experiment 2 109496 3146
LOU/M time from therapy-induced maximal immunocytoma size decrease to regrowth of tumor to a diameter of 10 mm rat IgM immunocytoma cells (1 x 10E4 cells) then cisplatin (0.5 mg/kg) (for 7 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 4.6 d 2.6 in vivo caliper method 0.0 0 Experiment 2 109497 3146
LOU/M experimental autoimmune encephalomyelitis duration Freund's complete adjuvant (0.05-0.1 ml) and Hu-S102-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 3 8.0 d 0.0 0.0 in vivo visual assessment 2592000.0 0 110802 3186
LOU/M liver adult Schistosoma mansoni worm count rat anti-Ab2 T cell line (10-15 x 10E6 cells) (for 90 days) then Schistosoma mansoni cercariae (1500 null) (for 21 days) Velge-Roussel F, etal., J Immunol. 1991 Dec 1;147(11):3967-72. parasite quantity male 201 days 3 count 64.0 null total organ perfusion and parasite count liver 0.0 90 days total organ perfusion and parasite count (MMO:0000750) 109270 3139
LOU/M liver adult Schistosoma mansoni worm count rat anti-26 kDa T cell line (10-15 x 10E6 cells) (for 90 days) then Schistosoma mansoni cercariae (1500 null) (for 21 days) Velge-Roussel F, etal., J Immunol. 1991 Dec 1;147(11):3967-72. parasite quantity male 201 days 3 count 67.0 null total organ perfusion and parasite count liver 0.0 90 days total organ perfusion and parasite count (MMO:0000750) 109271 3139
LOU/M liver adult Schistosoma mansoni worm count rat anti-control-Ab2 T cells (10-15 x 10E6 cells) (for 1 days) then Schistosoma mansoni cercariae (1500 null) (for 21 days) Velge-Roussel F, etal., J Immunol. 1991 Dec 1;147(11):3967-72. parasite quantity male 112 days 3 count 154.0 null total organ perfusion and parasite count liver 0.0 1 days total organ perfusion and parasite count (MMO:0000750) 109241 3139
LOU/M post-treatment survival time from drug-treated IgM immunocytoma rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (16 mg/kg) (for 28 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. life span trait both 154 days-193 days 5 26.0 d 0.89 2.0 necropsy 0.0 0 post-treatment survival time from drug-treated IgM immunocytoma (CMO:0003867) 109470 3146
LOU/M post-treatment survival time from drug-treated IgM immunocytoma rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (4 mg/kg) (for 49 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. life span trait both 154 days-193 days 7 35.0 d 0.76 2.0 necropsy 0.0 0 post-treatment survival time from drug-treated IgM immunocytoma (CMO:0003867) 109472 3146
LOU/M maximum tumor size decrease to pretreatment tumor size ratio rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (1 mg/kg) (for 21 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 90.8 % 12.7 in vivo caliper method 0.0 0 Experiment 1 109482 3146
LOU/M maximum tumor size decrease to pretreatment tumor size ratio rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (2 mg/kg) (for 21 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 78.5 % 16.7 in vivo caliper method 0.0 0 Experiment 1 109483 3146
LOU/M time from start of drug therapy to immunocytoma regrowth rat IgM immunocytoma cells (1 x 10E4 cells) then cisplatin (1 mg/kg) (for 35 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 35.0 d 7.7 in vivo caliper method 0.0 0 Experiment 1 109484 3146
LOU/M maximum tumor size decrease to pretreatment tumor size ratio rat IgM immunocytoma cells (1 x 10E4 cells) then cisplatin (0.5 mg/kg) (for 21 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 66.7 % 25.4 in vivo caliper method 0.0 0 Experiment 2 109488 3146
LOU/M percent protection by treatment for Schistosoma mansoni rat serum from subject bearing a B48-14 IgE-producing hybridoma (0.5 ml) then Schistosoma mansoni cercariae (800 null) Verwaerde C, etal., J Immunol. 1987 Jun 15;138(12):4441-6. response to parasitic infection trait male 111 days 5 (a-b/a)x100 63.0 % total organ perfusion and parasite count liver 0.0 Schistosoma mansoni cercariae 21 days compared to saline, experiment 1 110808 3190
LOU/M experimental autoimmune encephalomyelitis duration Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) and cyclophosphamide (8 mg) then cyclophosphamide (5 mg) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 4 11.0 d 0.0 0.0 in vivo visual assessment 2592000.0 0 110801 3186
LOU/M experimental autoimmune encephalomyelitis duration Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 4 8.0 d 0.0 0.0 in vivo visual assessment 2592000.0 0 110803 3186
LOU/M percentage of study population developing experimental autoimmune encephalomyelitis during a period of time Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 4 0.0 % 0.0 0.0 in vivo visual assessment 2592000.0 0 110791 3186
LOU/M time from start of drug therapy to immunocytoma regrowth rat IgM immunocytoma cells (1 x 10E4 cells) then cisplatin (1 mg/kg) (for 21 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 21.6 d 1.3 in vivo caliper method 0.0 0 Experiment 2 109494 3146
LOU/M percentage of study population developing experimental autoimmune encephalomyelitis during a period of time rat anti-Hu-S102-129 T cell line (9 x 10E6 cells) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 3 100.0 % in vivo visual assessment 0.0 0 110781 3186
LOU/M experimental autoimmune encephalomyelitis duration rat anti-Hu-MBP T cell line (9 x 10E6 cells) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 9 6.0 d 1.0 3.0 in vivo visual assessment 0.0 0 110784 3186
LOU/M percent protection by treatment for Schistosoma mansoni rat anti-Ab2 T cell line (10-15 x 10E6 cells) (for 1 days) then Schistosoma mansoni cercariae (1500 null) (for 21 days) Velge-Roussel F, etal., J Immunol. 1991 Dec 1;147(11):3967-72. response to parasitic infection trait male 112 days 3 (a-b/a)x100 0.0 % computational method 0.0 1 days S. mansoni infection 1 day post pretreatment 109248 3139
LOU/M percent protection by treatment for Schistosoma mansoni rat anti-26 kDa T cell line (10-15 x 10E6 cells) (for 90 days) then Schistosoma mansoni cercariae (1500 null) (for 21 days) Velge-Roussel F, etal., J Immunol. 1991 Dec 1;147(11):3967-72. response to parasitic infection trait male 201 days 3 (a-b/a)x100 55.0 % computational method 0.0 90 days S. mansoni infection 90 day post pretreatment 109259 3139
LOU/M liver adult Schistosoma mansoni worm count rat anti-Ab2 T cells (10-15 x 10E6 cells) (for 1 days) then Schistosoma mansoni cercariae (1500 null) (for 21 days) Velge-Roussel F, etal., J Immunol. 1991 Dec 1;147(11):3967-72. parasite quantity male 112 days 3 count 112.0 null total organ perfusion and parasite count liver 0.0 1 days total organ perfusion and parasite count (MMO:0000750) 109266 3139
LOU/M liver adult Schistosoma mansoni worm count rat anti-control-Ab2 T cell line (10-15 x 10E6 cells) (for 1 days) then Schistosoma mansoni cercariae (1500 null) (for 21 days) Velge-Roussel F, etal., J Immunol. 1991 Dec 1;147(11):3967-72. parasite quantity male 112 days 3 count 129.0 null total organ perfusion and parasite count liver 0.0 1 days total organ perfusion and parasite count (MMO:0000750) 109267 3139
LOU/M liver adult Schistosoma mansoni worm count rat anti-control-Ab2 T cell line (10-15 x 10E6 cells) (for 90 days) then Schistosoma mansoni cercariae (1500 null) (for 21 days) Velge-Roussel F, etal., J Immunol. 1991 Dec 1;147(11):3967-72. parasite quantity male 201 days 3 count 149.0 null total organ perfusion and parasite count liver 0.0 90 days total organ perfusion and parasite count (MMO:0000750) 109269 3139
LOU/M time from start of drug therapy to immunocytoma regrowth rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (2 mg/kg) (for 28 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. hypodermis integrity trait both 154 days-193 days 0 26.1 d 7.1 in vivo caliper method 0.0 0 Experiment 1 109486 3146